These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23544584)

  • 21. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies.
    Negi LM; Talegaonkar S; Jaggi M; Verma AK; Verma R; Dobhal S; Kumar V
    Colloids Surf B Biointerfaces; 2014 Nov; 123():610-5. PubMed ID: 25454755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer cell specific targeting of nanogels from acetylated hyaluronic acid with low molecular weight.
    Park W; Kim KS; Bae BC; Kim YH; Na K
    Eur J Pharm Sci; 2010 Jul; 40(4):367-75. PubMed ID: 20417709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
    Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
    Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal delivery of hyaluronic acid -- human growth hormone conjugate.
    Yang JA; Kim ES; Kwon JH; Kim H; Shin JH; Yun SH; Choi KY; Hahn SK
    Biomaterials; 2012 Sep; 33(25):5947-54. PubMed ID: 22632765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-assembled nanoparticles of hyaluronic acid/poly(DL-lactide-co-glycolide) block copolymer.
    Jeong YI; Kim DH; Chung CW; Yoo JJ; Choi KH; Kim CH; Ha SH; Kang DH
    Colloids Surf B Biointerfaces; 2012 Feb; 90():28-35. PubMed ID: 22001557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
    Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
    J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
    Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
    J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and Paclitaxel based on hyaluronic acid-based multifunctional nanocarrier.
    Yao J; Zhang L; Zhou J; Liu H; Zhang Q
    Mol Pharm; 2013 Mar; 10(3):1080-91. PubMed ID: 23320642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design of novel BSA/hyaluronic acid nanodispersions for transdermal pharma purposes.
    Martins M; Azoia NG; Shimanovich U; Matamá T; Gomes AC; Silva C; Cavaco-Paulo A
    Mol Pharm; 2014 May; 11(5):1479-88. PubMed ID: 24649886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers.
    He M; Zhao Z; Yin L; Tang C; Yin C
    Int J Pharm; 2009 May; 373(1-2):165-73. PubMed ID: 19429302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing the transdermal penetration of nanoconstructs: could hyaluronic acid be the key?
    Jung HS; Kim KS; Yun SH; Hahn SK
    Nanomedicine (Lond); 2014 May; 9(6):743-5. PubMed ID: 24981644
    [No Abstract]   [Full Text] [Related]  

  • 33. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy.
    Xu K; Lee F; Gao SJ; Chung JE; Yano H; Kurisawa M
    J Control Release; 2013 Mar; 166(3):203-10. PubMed ID: 23328125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fabrication of biocompatible and tumor-targeting hyaluronan nanospheres by a modified desolvation method.
    Zheng W; Li Y; Du J; Yin Z
    J Pharm Sci; 2014 May; 103(5):1529-37. PubMed ID: 24604299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies.
    El-Laithy HM; Shoukry O; Mahran LG
    Eur J Pharm Biopharm; 2011 Jan; 77(1):43-55. PubMed ID: 21056658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced topical delivery of hyaluronic acid encapsulated in liposomes: A surface-dependent phenomenon.
    Vázquez-González ML; Calpena AC; Domènech Ò; Montero MT; Borrell JH
    Colloids Surf B Biointerfaces; 2015 Oct; 134():31-9. PubMed ID: 26142626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyaluronate tethered, "smart" multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin.
    Datir SR; Das M; Singh RP; Jain S
    Bioconjug Chem; 2012 Nov; 23(11):2201-13. PubMed ID: 23039830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyaluronic acid and HA-modified cationic liposomes for promoting skin penetration and retention.
    Ni C; Zhang Z; Wang Y; Zhang Z; Guo X; Lv H
    J Control Release; 2023 May; 357():432-443. PubMed ID: 37004799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A transdermal delivery system to enhance quercetin nanoparticle permeability.
    Bennet D; Kim S
    J Biomater Sci Polym Ed; 2013; 24(2):185-209. PubMed ID: 23565597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
    Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
    J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.